phs001572
Pan-tumor genomic biomarkers for personalization of PD-1 checkpoint blockade based immunotherapy
Tumor mutation burden (TMB) and a T-cell-inflamed gene expression profile (GEP) independently predict clinical outcome in pembrolizumab-treated patients in 22 indications and stratify distinct targets of resistance biology.